Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

详细信息    查看全文

• 作者：Giovanni Palladini ; Paola Russo ; Francesca Lavatelli ; Mario Nuvolone ; Riccardo Albertini ; Tiziana Bosoni ; Vittorio Perfetti ; Laura Obici ; Stefano Perlini and Remigio Moratti ; et al.
• 关键词：Amyloidosis ; Melphalan ; Dexamethasone ; Thalidomide ; Response
• 刊名：Annals of Hematology
• 出版年：2009
• 出版时间：April, 2009
• 年：2009
• 卷：88
• 期：4
• 页码：347-350
• 全文大小：90.2 KB

文摘

Patients with primary (AL) amyloidosis and heart failure have a very poor prognosis and cannot tolerate aggressive therapy, such as autologous stem cell transplantation and high-dose dexamethasone-based regimens. We prospectively treated 22 patients with advanced cardiac amyloidosis combining oral melphalan, thalidomide, and reduced intensity dexamethasone (MTD). Six patients died due to cardiac amyloidosis before completing cycle 3. Early death was associated with reduced ejection fraction. Eight patients achieved a hematological response and four achieved a durable improvement of cardiac dysfunction. Treatment with MTD is feasible in patients with advanced cardiac AL amyloidosis and effective in subjects with preserved systolic function.